Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q4 2019 · 10-K
Revenue$1.92M$1.92M+20.0% vs Q4 2018 Net Income-$1.10M-$1.10MN/M vs Q4 2018 EPS Diluted-$0.02-$0.02N/M vs Q4 2018 Gross Profit$879,000+98.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$985,000N/M Free Cash Flowderived-$1,076,000N/M Margins · derivedGross margin45.7%+18.1 pt vs Q4 2018
Operating margin-59.5%+88.4 pt vs Q4 2018
Net margin-56.9%+89.3 pt vs Q4 2018
ended Jun 30, 2019 · filed Sep 27, 2019 · 89 d after period end